J&J Pays Doctors $6.93 Million to Promote Xarelto in 2013
Johnson & Johnson paid doctors nearly $7 million during the first half of 2013 to promote a drug tied to Xarelto internal bleeding injuries, according to a recent analysis.
The study, which can be found in Pro Publica, looked at cash amounts shelled out by top manufacturers during the last five months of the year. The findings were obtained through Sunshine Act data, and also pinpointed payments paid to push the diabetes medication, Victoza, and the blood-thinning drug, Pradaxa at $4.43 million. Xarelto was the sixth most highly paid drug in the U.S., at $6.93 million.
The results of this analysis are noteworthy for a number of reasons. First off, Xarelto only received U.S. Food and Drug Administration (FDA) approval in 2011, when it was cleared for the prevention of strokes, heart attacks and other cardiovascular problems in patients with atrial fibrillation, as well as to treat deep vein thrombosis and pulmonary embolism. The medication, which is jointly marketed by Johnson & Johnson’s Janssen unit and Bayer HealthCare, is also approved to reduce the risk of blood clots in patients undergoing hip replacement surgeries.
Xarelto Manufacturers Fail to Properly Warn about Severity of Internal Bleeding Injuries, Lawsuits Allege
The use of Xarelto has also been associated with serious episodes of internal bleeding, which may be life-threatening because there is no available antidote to stop them. Its manufacturers fail to note this in its marketing of the medication, which plaintiffs cite in their lawsuits that seek compensation for a myriad of blood thinner-injury related damages. Xarelto’s manufacturers instead tout its convenience over warfarin, a similar product that requires patients to seek routine monitoring of blood levels. The decades-old blood thinner has also been tied to life-threatening bleeding injuries, which can be stopped with the administration of Vitamin K.
In December 2014, similar lawsuits against the makers of Xarelto were centralized in a federal multidistrict litigation established in the U.S. District Court, Eastern District of Louisiana. There, cases alleging episodes of internal bleeding caused by the drug, as well as other complications have been consolidated for pre-trial proceedings. These Xarelto lawsuits accuse Janssen and Bayer Healthcare of failing to adequately warn about side effects that may stem from use of its product.
Consider a Xarelto Lawsuit
Call a Xarelto lawyer at our Firm today for more about lawsuits over the blood thinner. Contact us directly at (877) 779-1414.